J Eriksson1, O Norlén1, M Ögren1, H Garmo2,3, C Ihre-Lundgren4, P Hellman1. 1. Department of Surgical Sciences, Uppsala University Hospital, Uppsala, Sweden. 2. Division of Cancer Studies, Cancer Epidemiology Group, Research Oncology, King's College London, London, UK. 3. Regional Oncologic Centre, Uppsala University, Uppsala, Sweden. 4. Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Abstract
BACKGROUND: Small intestinal neuroendocrine tumors are the most common of small bowel malignancies with a clinical incidence of about 1 per 100,000 persons per year. There has been a threefold increase in the incidence of small intestinal neuroendocrine tumor during later decades, but there are no studies that clarify whether this is due to a true higher incidence or if the rise is a mere product of, for instance, improved diagnostic modalities. The aim of this study was to investigate the incidence of clinical as well as subclinical small intestinal neuroendocrine tumors found at autopsy as well as describing the frequency of concomitant malignancies in patients with small intestinal neuroendocrine tumor. MATERIALS AND METHODS: An autopsy registry from the Malmö county population from 1970 to 1982 with an 87% autopsy rate was used. The clinical autopsy reports for patients coded for the existence of "carcinoid tumor" were scrutinized for the presence of small intestinal neuroendocrine tumor, metastatic disease, and concomitant malignancies. Details of patients with clinically diagnosed small intestinal neuroendocrine tumor during this time period were gathered from the Swedish Cancer Registry. RESULTS: The mean annual incidence of small intestinal neuroendocrine tumor during this period was 5.33 per 100,000 individuals, and the mean annual prevalence was 581 per 100,000. The cause of death in the majority of cases was not due to small intestinal neuroendocrine tumor. In total, 48% of the people with small intestinal neuroendocrine tumor had at least one other malignancy, most commonly colorectal cancer. CONCLUSION: Most small intestinal neuroendocrine tumors are subclinical, and persons living with them will often die due to other causes. There was a high rate of multiple primary tumors (40%), suggesting that multiple tumors seem to arise before the advent of metastatic disease. Moreover, a comparably high rate of associated colorectal carcinoma was found.
BACKGROUND: Small intestinal neuroendocrine tumors are the most common of small bowel malignancies with a clinical incidence of about 1 per 100,000 persons per year. There has been a threefold increase in the incidence of small intestinal neuroendocrine tumor during later decades, but there are no studies that clarify whether this is due to a true higher incidence or if the rise is a mere product of, for instance, improved diagnostic modalities. The aim of this study was to investigate the incidence of clinical as well as subclinical small intestinal neuroendocrine tumors found at autopsy as well as describing the frequency of concomitant malignancies in patients with small intestinal neuroendocrine tumor. MATERIALS AND METHODS: An autopsy registry from the Malmö county population from 1970 to 1982 with an 87% autopsy rate was used. The clinical autopsy reports for patients coded for the existence of "carcinoid tumor" were scrutinized for the presence of small intestinal neuroendocrine tumor, metastatic disease, and concomitant malignancies. Details of patients with clinically diagnosed small intestinal neuroendocrine tumor during this time period were gathered from the Swedish Cancer Registry. RESULTS: The mean annual incidence of small intestinal neuroendocrine tumor during this period was 5.33 per 100,000 individuals, and the mean annual prevalence was 581 per 100,000. The cause of death in the majority of cases was not due to small intestinal neuroendocrine tumor. In total, 48% of the people with small intestinal neuroendocrine tumor had at least one other malignancy, most commonly colorectal cancer. CONCLUSION: Most small intestinal neuroendocrine tumors are subclinical, and persons living with them will often die due to other causes. There was a high rate of multiple primary tumors (40%), suggesting that multiple tumors seem to arise before the advent of metastatic disease. Moreover, a comparably high rate of associated colorectal carcinoma was found.
Authors: Maximilian Evers; Anja Rinke; Johannes Rütz; Annette Ramaswamy; Elisabeth Maurer; Detlef K Bartsch Journal: World J Surg Date: 2021-01-08 Impact factor: 3.352
Authors: Ken Ho; Maria Fleseriu; Ursula Kaiser; Roberto Salvatori; Thierry Brue; M Beatriz Lopes; Pamela Kunz; Mark Molitch; Sally A Camper; Mônica Gadelha; Luis V Syro; Edward Laws; Martin Reincke; Hiroshi Nishioka; Ashley Grossman; Ariel Barkan; Felipe Casanueva; John Wass; Adam Mamelak; Laurence Katznelson; Aart J van der Lely; Sally Radovick; Martin Bidlingmaier; Margaret Boguszewski; Jens Bollerslev; Andrew R Hoffman; Nelson Oyesiku; Gerald Raverot; Anat Ben-Shlomo; Rob Fowkes; Ilan Shimon; Hidenori Fukuoka; Alberto M Pereira; Yona Greenman; Anthony P Heaney; Mark Gurnell; Gudmundur Johannsson; Robert Y Osamura; Michael Buchfelder; Maria Chiara Zatelli; Marta Korbonits; Philippe Chanson; Nienke Biermasz; David R Clemmons; Niki Karavitaki; Marcello D Bronstein; Peter Trainer; Shlomo Melmed Journal: J Endocr Soc Date: 2021-02-09
Authors: Benjamin E White; Brian Rous; Kandiah Chandrakumaran; Kwok Wong; Catherine Bouvier; Mieke Van Hemelrijck; Gincy George; Beth Russell; Rajaventhan Srirajaskanthan; John K Ramage Journal: Lancet Reg Health Eur Date: 2022-09-23